Summary by Futu AI
Aclarion, Inc., a healthcare technology company, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on September 6, 2024. The filing indicates Aclarion's intent to offer and sell securities, including common stock, preferred stock, warrants, subscription rights, debt securities, and units, up to a total gross proceeds of $50,000,000. The securities may be offered from time to time in one or more series, and the proceeds are intended for market development, clinical evidence, product development, general administration support, and other corporate purposes. Aclarion's common stock is quoted on the Nasdaq Capital Market under the symbol 'ACON.' The company has also detailed its indemnification policy for directors and officers, stating that it will provide mandatory indemnification to the fullest extent permitted by law. The registration statement includes various legal and financial documents, such as the company's bylaws, certificate of incorporation, and financial statements audited by Haynie & Company and CohnReznick LLP.